David Henry's JCSO Podcast

David Henry's JCSO podcast, September-October 2017

Submit a paper here


 

In this podcast, coinciding with breast cancer awareness month, Dr David Henry highlights an article by contributor Jane de Lartigue on recent advances in the use of targeted therapies in multiple breast cancer subtypes and another by a practicing oncologist on the positive impact of centralizing breast cancer care in an urban public hospital. Patient-reported outcomes are the focus a review on PROs in palliative and supportive interventions rural cancer patients and an original research report on findings on adverse events from systemic treatment of cancer and patient-reported quality of life. Also featured are two Community Translations columns on the approvals for atezolizumab for non–small-cell lung cancer and lenalidomide as standard of care for multiple myeloma in the maintenance setting, and two case reports on familial essential thrombocythemia associated with JAK2 V617F mutation in siblings and on managing tonsillar carcinoma with advanced radiation and chemotherapy techniques.

Listen to the podcast below.

Recommended Reading

Assessing a multidisciplinary survivorship program in a group of predominantly Hispanic women with breast cancer
MDedge Hematology and Oncology
Ten-year outcomes support skipping axillary lymph node dissection with positive sentinel nodes
MDedge Hematology and Oncology
Surgeons strongly influenced chances of contralateral prophylactic mastectomy
MDedge Hematology and Oncology
LORELEI sings praises of neoadjuvant taselisib/letrozole in ER+/HER2– breast cancer
MDedge Hematology and Oncology
MONARCH 3: Abemaciclib plus AI boosts PFS in HR+/HER2- breast cancer
MDedge Hematology and Oncology
‘Very daring study’ of neoadjuvant AI/CDKi combo in early BC is hypothesis generating
MDedge Hematology and Oncology
GEICAM/2006-10: Adjuvant fulvestrant/anastrozole role in early breast cancer uncertain
MDedge Hematology and Oncology
HER2 status differed between primary tumor and CTCs in 18.8% of women with MBC
MDedge Hematology and Oncology
FDA approves abemaciclib for advanced breast cancer
MDedge Hematology and Oncology
Two cases of possible remission in metastatic triple-negative breast cancer
MDedge Hematology and Oncology